<p>|Recommendation|Level of evidence (evidence [refs.] reviewed)†|
|---|---|
|In adult patients with active PsA despite treatment with a TNFi biologic monotherapy,| |
|1. Switch to a different TNFi biologic over switching to an IL-17i biologic (PICO 28)|Low (72, 73, 90–93, 95)|
|Conditional recommendation based on low-quality evidence; may consider an IL-17i if the patient had a primary TNFi biologic efficacy failure or a TNFi biologic–associated serious adverse event or severe psoriasis.‡| |